ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements
Q2 FY27 revenue INR795 cr (+40% YoY), EBITDA INR115 cr (14.4% margin), PAT INR65 cr (+117%). Management now guides ~25%+ FY27 revenue growth.
IOL Chemicals delivered strong Q2 results with significant profitability improvements, driven by non-Ibuprofen API growth and cost efficiencies, despite rising raw material prices.
Q2 FY27 standalone revenue ₹795 Cr (+40.1% YoY), EBITDA ₹114.9 Cr (14.4% margin), PAT ₹65 Cr (+116.8%). H1 revenue ₹1,551 Cr (+38.6%). Pivoting to high-value APIs with ₹495 Cr capex plan.
IOL Chemicals reported record quarterly revenue, EBITDA and profit for Q2 FY27 and half-year results. Standalone growth was strong, with margins expanding year-on-year.
IOL Chemicals and Pharmaceuticals Ltd reported revenue from operations of ₹795 Cr (+40.1% YoY) and net profit of ₹65.1 Cr (+117.0% YoY) for Q2 FY27.
IOL Chemicals scheduled its board meeting for 30 Oct 2026 to consider unaudited Q1/H1 results. Trading window remains closed until 2 Nov 2026.
The company submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.
IOL Chemicals and Pharmaceuticals Limited received EU-REACH registration for its product 'Triacetin', enabling the company to export this product to countries in the European Union.
IOL Chemicals and Pharmaceuticals Limited informed the Exchange about the dispatch of reminder letters to shareholders holding physical shares for updating their KYC details.
IOL Chemicals announced three strategic initiatives involving INR 500 Cr investment: Ibuprofen capacity expansion (to 18,000 MTPA), a new CDMO formulations facility, and a dedicated specialty chemical tolling facility.
IOL Chemicals and Pharmaceuticals Ltd will expand Ibuprofen capacity by 6,000 MTPA. The project, requiring a ₹350 Crore investment, is expected to be commercialized by December 2027.
IOLCP announces three capacity expansions at Barnala: 6,000 MTPA Ibuprofen unit, CDMO formulation facility, and specialty chemicals tolling plant. Total investment ₹495 Crore funded via internal accruals.
IOL Chemicals and Pharmaceuticals Limited held its 39th Annual General Meeting on September 2, 2026. Members approved the audited financial statements and director re-appointment with requisite majority.
IOL delivers a strong Q1FY27 beat driven by a 67% revenue jump in non-ibuprofen APIs and improved operating leverage.
IOLCP reported strong Q1 FY27 results with Revenue at ₹756.3 Cr (up 37.1% YoY) and PAT at ₹64.5 Cr (up 89.9% YoY). The company is strategically shifting towards high-value non-Ibuprofen APIs.
IOL Chemicals reported Q1 FY27 revenue of Rs. 756.3 Crore, with EBITDA and PAT of Rs. 111.7 Crore and Rs. 64.5 Crore respectively.
IOL Chemicals and Pharmaceuticals Ltd reported revenue from operations of ₹756.3 Cr (+37.1% YoY) and net profit of ₹64.4 Cr (+90.0% YoY) for Q1 FY27.
IOL Chemicals and Pharmaceuticals Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 in compliance with SEBI regulations.
IOL Chemicals and Pharmaceuticals Ltd has submitted its Integrated Annual Report for FY 2025-26. The report also contains the notice for the 39th Annual General Meeting.
IOL Chemicals and Pharmaceuticals Limited has filed the notice for its 39th Annual General Meeting scheduled for September 2, 2026. The meeting will be held via video conferencing.
IOL Chemicals and Pharmaceuticals Limited scheduled a board meeting on 10th August 2026 to approve unaudited financial results for the quarter ended 30th June 2026.
IOL Chemicals received NMPA China approval for its Clopidogrel Bisulfate API. This strengthens its regulatory portfolio and expands access to the Chinese pharmaceutical market.
CARE Ratings reaffirmed ratings for IOL Chemicals' banking facilities totaling ₹700 Crore. Long-term facilities are rated CARE A+ Stable; short-term rated CARE A1+.
NM Merchantiles Limited acquired a 4.80% stake in IOL Chemicals via an off-market merger. The promoter group's total holding increased to 21.88%.
IOL Chemicals is reminding shareholders to claim unclaimed dividends and update KYC to avoid IEPF transfer. This is a routine compliance communication with no material financial impact.
A minor fire at IOLCP's Minoxidil unit halted operations for 8-10 days. No injuries or material damage occurred, and other units run normally.
IOL reported record Q4 FY26 revenue of ₹619cr (up 17.4% YoY) and PAT of ₹53cr (up 68% YoY), driven by diversification into non-Ibuprofen APIs and improved chemical segment realization.
IOL reported strong growth in Q4 FY26 with revenue up 17.4% YoY. The company is strategically shifting towards high-value non-Ibuprofen APIs and expanding specialty chemical capacities.
IOL Chemicals reported ₹2,319.1 Crore FY26 revenue with 12.4% EBITDA margins. The company achieved highest-ever quarterly revenue, driven by strong growth in Pharma and Chemicals segments.
IOL Chemicals submitted its Annual Secretarial Compliance Report for FY2026. The report notes minor regulatory fines paid for a filing delay and past board vacancy.